Conference proceeding · Aug 2020
Conference abstractPublished 27 Oct 2014
Biosimilars: Regulatory approval pathway
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The expiration of patents for a number of blockbuster biologics, increasing pressure for lower cost versions of biological Medicines, ushered in an era of the subsequent production of biosimilar products. A biosimilar medicinal product is a biological medicine which is similar to another biological medicine that has already been authorized for use, the ?reference medicinal product? expected to have the same safety and efficacy profile. The EMA has taken the lead in the regulatory approval framework for biosimilar products, and WHO has published guidelines on the evaluation of biosimilars in order to facilitate the global harmonization. Biosimilarauthorization poses a number of substantial scientific and regulatory challenges for regulatory authorities. Committee for Medicinal Products for Human Use (CHMP) has also issued several product classspecific guidance that sets out product requirements in greater detail. The basic concepts and main principles of approving biosimilars are similar among various nations, notwithstanding some differences in regard to the scope, the choice of reference product, and the data requirement.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 19 Oct 2016
Biosimilars: Latin Americas coming on board: Regulatory approval and market access
Conference abstract · 19 Oct 2016
Biosimilars: Latin America´s Coming On Board: Regulatory Approval and Market Access
Conference abstract · 27 Jun 2016
Regulatory Update and Overview of Specific Scientific Issues for Development and Approval of Biosimilars in US
Conference abstract · 27 Oct 2014
Biosimilars and emerging challenges: Navigating pathway to approval, patent issues, and the exclusivity period
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Ghayaz”

